实用医学杂志 ›› 2022, Vol. 38 ›› Issue (11): 1309-1313.doi: 10.3969/j.issn.1006⁃5725.2022.11.002

• 专题报道 • 上一篇    下一篇

替罗非班在治疗急性缺血性卒中的应用及研究进展

石恒1,2 侯苗苗1 孙博1 刘晓蕾1 李新毅1   

  1. 1 山西医科大学第三医院(山西白求恩医院,山西医学科学院,同济山西医院)(太原 030032);2 山西医科大 学第三临床医学院(太原 030000)

  • 出版日期:2022-06-10 发布日期:2022-06-10
  • 通讯作者: 李新毅 E⁃mail:xinyili2003@163.com
  • 基金资助:

    山西省回国留学人员科研资助项目(编号:HG⁃KY2019096);山西省卫生健康委员会科研课题青年基金(编号:2022011)


Application and research progress of Tirofiban in the treatment of acute ischemic stroke

SHI Heng*,HOU Miaomiao,SUN Bo,LIU Xiaolei,LI Xinyi.   

  1. Third Hospital of Shanxi Medical University,Shanxi Bethune Hospi⁃ tal,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan 030032,China;*Third Clinical Medi⁃ cal College of Shanxi Medical University,Taiyuan 030000,China 

  • Online:2022-06-10 Published:2022-06-10
  • Contact: LI Xinyi E⁃mail:xinyili2003@163.com

摘要:

急性缺血性卒中是脑组织缺血缺氧而引起神经功能损伤的临床综合征,抗血小板治疗是缺 血性卒中预防及治疗的基础,替罗非班作为一种 GP Ⅱb/Ⅲa 受体抑制剂的新型抗血小板药物,在心血管 疾病应用已经基本成熟,但是在脑血管疾病中的应用仍处于探索阶段,具体用法用量及安全性仍有较多 争议,现就替罗非班在急性缺血性卒中治疗中的应用及研究进展进行综述。

关键词: 替罗非班, 急性缺血性卒中, 抗血小板, 静脉溶栓, 机械取栓

Abstract:

Acute ischemic stroke is a clinical syndrome manifesting nerve function impairment caused by brain ischemia and hypoxia. Antiplatelet therapy is the basis for the prevention and treatment of acute cerebral infarction. As a novel antiplatelet drug and inhibitor of GP IIb/IIIa receptor,tirofiban has been basically mature in the treatment of cardiovascular diseases. However,application of tirofiban for cerebrovascular diseases is still in the exploratory stage,and the administration routes,dosage and safety are still controversial. This paper reviews the application and research progress of tirofiban in the treatment of acute ischemic stroke.

Key words:

Tirofiban, acute ischemic stroke, antiplatelet, intravenous thrombolysis, mechanical thrombectomy